Compare Stocks: LXEO, ALVO, TRAX, and BCAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.21 +0.4%	$4.03	$2.94 ▼ $9.25	$1.57B	0.22	1.00 million shs	572,359 shs
BCAX Bicara Therapeutics	$23.64 -0.3%	$26.13	$10.30 ▼ $30.99	$1.57B	-0.82	486,957 shs	550,206 shs
LXEO Lexeo Therapeutics	$4.48 -5.9%	$4.74	$3.99 ▼ $10.99	$390.54M	1.5	689,445 shs	311,581 shs
TRAX First Tracks Biotherapeutics	$39.57 -5.3%	$39.56	$14.72 ▼ $49.91	$1.49B	N/A	570,468 shs	478,635 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+0.39%	-2.43%	+38.20%	+23.46%	-35.76%
BCAX Bicara Therapeutics	-0.30%	+0.34%	-14.75%	+11.09%	+89.73%
LXEO Lexeo Therapeutics	-5.88%	-6.28%	-3.24%	+6.67%	-13.68%
TRAX First Tracks Biotherapeutics	-5.33%	-12.61%	-17.42%	+132.35%	+3,956,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.21 +0.4%	$4.03	$2.94 ▼ $9.25	$1.57B	0.22	1.00 million shs	572,359 shs
BCAX Bicara Therapeutics	$23.64 -0.3%	$26.13	$10.30 ▼ $30.99	$1.57B	-0.82	486,957 shs	550,206 shs
LXEO Lexeo Therapeutics	$4.48 -5.9%	$4.74	$3.99 ▼ $10.99	$390.54M	1.5	689,445 shs	311,581 shs
TRAX First Tracks Biotherapeutics	$39.57 -5.3%	$39.56	$14.72 ▼ $49.91	$1.49B	N/A	570,468 shs	478,635 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+0.39%	-2.43%	+38.20%	+23.46%	-35.76%
BCAX Bicara Therapeutics	-0.30%	+0.34%	-14.75%	+11.09%	+89.73%
LXEO Lexeo Therapeutics	-5.88%	-6.28%	-3.24%	+6.67%	-13.68%
TRAX First Tracks Biotherapeutics	-5.33%	-12.61%	-17.42%	+132.35%	+3,956,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.25	Hold	$7.50	43.95% Upside
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	38.06% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	318.53% Upside
TRAX First Tracks Biotherapeutics	2.73	Moderate Buy	$63.00	59.21% Upside

Current Analyst Ratings Breakdown

Latest LXEO, ALVO, TRAX, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	TRAX First Tracks Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00
8/31/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	ALVO Alvotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	TRAX First Tracks Biotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$83.00
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	TRAX First Tracks Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/13/2026	TRAX First Tracks Biotherapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$54.00 ➝ $95.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$588.90M	2.67	$0.22 per share	23.82	($0.94) per share	-5.54
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.61	N/A	21.71	N/A	-36.31%	-11.92%	-11.73%	11/11/2026 (Estimated)
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
TRAX First Tracks Biotherapeutics	N/A	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest LXEO, ALVO, TRAX, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.22	$103.00 million	$106.00 million
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/12/2026	Q2 2026	TRAX First Tracks Biotherapeutics	-$0.74	-$0.95	-$0.21	-$0.95	N/A	N/A
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.65	0.96
BCAX Bicara Therapeutics	N/A	11.59	11.59
LXEO Lexeo Therapeutics	N/A	13.89	13.89
TRAX First Tracks Biotherapeutics	N/A	14.28	14.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
BCAX Bicara Therapeutics	N/A
LXEO Lexeo Therapeutics	60.67%
TRAX First Tracks Biotherapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
BCAX Bicara Therapeutics	13.80%
LXEO Lexeo Therapeutics	2.00%
TRAX First Tracks Biotherapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	300.42 million	Not Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable
TRAX First Tracks Biotherapeutics	N/A	35.73 million	N/A	N/A

LXEO, ALVO, TRAX, and BCAX Headlines

Recent News About These Companies

J. Anthony Ware Sells 39,265 Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) Stock

September 5, 2026 | insidertrades.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Average Rating of "Moderate Buy" from Analysts

September 5, 2026 | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for First Tracks Biotherapeutics (NASDAQ:TRAX)

September 5, 2026 | americanbankingnews.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded by Wall Street Zen to "Sell"

September 5, 2026 | americanbankingnews.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded to "Sell" Rating by Wall Street Zen

September 5, 2026 | marketbeat.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock

September 4, 2026 | marketbeat.com

First Tracks Biotherapeutics' (TRAX) Buy Rating Reiterated at HC Wainwright

September 3, 2026 | marketbeat.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

First Tracks Biotherapeutics Inc (TRAX)

August 30, 2026 | de.investing.com

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

August 26, 2026 | globenewswire.com

Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)

August 18, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

August 17, 2026 | marketbeat.com

Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)

August 14, 2026 | theglobeandmail.com

Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)

August 14, 2026 | theglobeandmail.com

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

August 13, 2026 | benzinga.com

Wedbush Issues Positive Forecast for First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Price

August 13, 2026 | marketbeat.com

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026 | globenewswire.com

First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo

July 29, 2026 | theglobeandmail.com

TRAX stock hits all-time high — what's driving the super rally?

July 10, 2026 | msn.com

First Tracks Biotherapeutics Inc

June 30, 2026 | cnn.com

First Tracks Biotherapeutics Shares Edge Up on Sublease Deal

June 23, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ALVO, TRAX, and BCAX Company Descriptions

Alvotech NASDAQ:ALVO

$5.21 +0.02 (+0.39%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$5.22 +0.00 (+0.10%)

As of 09/9/2026 07:30 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Bicara Therapeutics NASDAQ:BCAX

$23.64 -0.07 (-0.30%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$23.50 -0.14 (-0.59%)

As of 08:47 AM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$4.48 -0.28 (-5.88%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$4.58 +0.11 (+2.34%)

As of 07:17 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

First Tracks Biotherapeutics NASDAQ:TRAX

$39.57 -2.23 (-5.33%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$40.18 +0.61 (+1.54%)

As of 07:55 AM Eastern

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXEO, ALVO, TRAX, and BCAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXEO, ALVO, TRAX, and BCAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXEO, ALVO, TRAX, and BCAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ALVO, TRAX, and BCAX Company Descriptions

Alvotech NASDAQ:ALVO

Bicara Therapeutics NASDAQ:BCAX

Lexeo Therapeutics NASDAQ:LXEO

First Tracks Biotherapeutics NASDAQ:TRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXEO, ALVO, TRAX, and BCAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXEO, ALVO, TRAX, and BCAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXEO, ALVO, TRAX, and BCAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ALVO, TRAX, and BCAX Company Descriptions

Alvotech NASDAQ:ALVO

Bicara Therapeutics NASDAQ:BCAX

Lexeo Therapeutics NASDAQ:LXEO

First Tracks Biotherapeutics NASDAQ:TRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools